Comment
doi: 10.1016/S1470-2045(22)00023-7.
Immune checkpoint inhibitors and timing of administration - Authors' reply
Affiliations
- PMID: 35114126
- DOI: 10.1016/S1470-2045(22)00023-7
Item in Clipboard
Comment
Immune checkpoint inhibitors and timing of administration - Authors' reply
Lancet Oncol.
2022 Feb.
No abstract available
Conflict of interest statement
ZSB reports patent royalties from Ultragenyx. DCQ declares no competing interests.
Comment in
-
Immune checkpoint inhibitors and timing of administration.Lancet Oncol. 2022 Feb;23(2):e55. doi: 10.1016/S1470-2045(21)00704-X. Lancet Oncol. 2022. PMID: 35114124 No abstract available.
-
Immune checkpoint inhibitors and timing of administration.Lancet Oncol. 2022 Feb;23(2):e56. doi: 10.1016/S1470-2045(22)00009-2. Lancet Oncol. 2022. PMID: 35114125 No abstract available.
Comment on
-
Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.Lancet Oncol. 2021 Dec;22(12):1777-1786. doi: 10.1016/S1470-2045(21)00546-5. Epub 2021 Nov 12. Lancet Oncol. 2021. PMID: 34780711 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
